Join

Compare · HEXO vs IMV

HEXO vs IMV

Side-by-side comparison of HEXO Corp. (HEXO) and IMV Inc. (IMV): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HEXO and IMV operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
  • HEXO is the larger of the two at $176.3M, about 2.0x IMV ($89.5M).
  • HEXO has more recent analyst coverage (11 ratings vs 2 for IMV).
MetricHEXOIMV
Company
HEXO Corp.
IMV Inc.
Price
$0.70+3.98%
$0.80+2.92%
Market cap
$176.3M
$89.5M
1M return
-
-
1Y return
-
-
Industry
Pharmaceuticals and Biotechnology
Pharmaceuticals and Biotechnology
Exchange
NYSE
NASDAQ
IPO
News (4w)
0
0
Recent ratings
11
2
HEXO

HEXO Corp.

HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. It offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. The company offers its adult-use and medical products under the HEXO brand name. Additionally, it offers cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brand; and cannabis products under Original Stash and Up brand names. The company was formerly known as The Hydropothecary Corporation and changes its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Kanata, Canada.

IMV

IMV Inc.

IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.